# CN Innovations

> CN Innovations is a VC fund in Hong Kong backing Energy, Medical and Biopharma. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Hong Kong, Hong Kong
- Total investments: 5
- Last investment: Apr 2024
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/cn-innovations-ltd/
- Website: http://www.cn-innovations.com/

CN Innovations is a science-based technology and precision engineering company. CN Innovations Holdings provides OEM technical and supply chain solutions to major industries.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Energy | 1 | 20% |
| Medical | 1 | 20% |
| Biopharma | 1 | 20% |
| Fuel Cell | 1 | 20% |
| Wearables | 1 | 20% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 40% |
| Series A | 1 | 20% |
| Series B | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Hong Kong | 1 | 20% |
| United States | 1 | 20% |
| United Kingdom | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CN Bio | CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based onthe culture of primary human hepatocytes in the company’s proprietary LiverChip® platform. The HBV disease model, which is referred to as Quantum-B®, is currently being deployed in drug discovery and research alliances with a number of leading pharmaceutical and biotech companies.Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next generation organ-on-chips which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market. | $21M | Series B | Apr 23, 2024 |  |
| Versogen | Versogen develops electrolyzer technology for water and renewable energy to produce green hydrogen at scale. The company produces high-performing hydroxide exchange membranes for a variety of applications, such as lowering the production costs of fuel cells and reducing industrial carbon emissions, and laying the foundation for a sustainable energyfuture. | $14.5M | Series A | May 10, 2022 |  |
| CN Bio | CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based onthe culture of primary human hepatocytes in the company’s proprietary LiverChip® platform. The HBV disease model, which is referred to as Quantum-B®, is currently being deployed in drug discovery and research alliances with a number of leading pharmaceutical and biotech companies.Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next generation organ-on-chips which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market. | $9M | Venture - Series Unknown | Mar 02, 2020 |  |
| Origami Labs Limited | Redefining the mobile computing experience through screen-free, voice and gesture-based products and services. | $510K | Seed | Jan 10, 2017 |  |
| CN Bio | CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based onthe culture of primary human hepatocytes in the company’s proprietary LiverChip® platform. The HBV disease model, which is referred to as Quantum-B®, is currently being deployed in drug discovery and research alliances with a number of leading pharmaceutical and biotech companies.Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next generation organ-on-chips which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market. |  | Seed |  |  |

5 of 5 investments shown.

## Co-investors
- [Alibaba Entrepreneurs Fund](https://shizune.co/investors/profile/alibaba-entrepreneurs-fund) — VC Fund, 1 deal together
- [America LLC](https://shizune.co/investors/profile/america-llc) — VC Fund, 1 deal together
- [Bayland Capital](https://shizune.co/investors/profile/bayland-capital) — VC Fund, 1 deal together
- [CITIC Securities](https://shizune.co/investors/profile/citic-securities) — VC Fund, 1 deal together
- [Click Ventures](https://shizune.co/investors/profile/click-venture-fund) — VC Fund, 1 deal together
- [Doosan Group](https://shizune.co/investors/profile/doosan-group) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Global Founders Capital](https://shizune.co/investors/profile/global-founders-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Alibaba Entrepreneurs Fund](https://shizune.co/investors/profile/alibaba-entrepreneurs-fund) — VC Fund
- [Animoca Brands](https://shizune.co/investors/profile/animoca-brands-corporation) — VC Fund
- [Gobi Partners](https://shizune.co/investors/profile/gobi-partners) — VC Fund

## Featured in investor lists
- [Hospitality Investors in Hong Kong](https://shizune.co/investors/hospitality-investors-hong-kong)
- [Hospitality VC Funds in Hong Kong](https://shizune.co/investors/hospitality-vc-funds-hong-kong)
- [Consumer VC Funds in Hong Kong](https://shizune.co/investors/consumer-vc-funds-hong-kong)
- [Hardware Investors in Hong Kong](https://shizune.co/investors/hardware-investors-hong-kong)
- [Hardware VC Funds in Hong Kong](https://shizune.co/investors/hardware-vc-funds-hong-kong)
- [Hospitality Investors in Asia](https://shizune.co/investors/hospitality-investors-asia)

## FAQ

### What does CN Innovations invest in?

CN Innovations invests primarily in Energy, Medical and Biopharma startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in Hong Kong. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did CN Innovations last invest?

The most recent investment recorded for CN Innovations closed in Apr 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co